5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista
5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista zbecker Mon, 03/11/2024 - 15:40
5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista zbecker Mon, 03/11/2024 - 15:40
FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard aliu Mon, 03/11/2024 - 14:45
Incyte's JAK cream Opzelura proves its worth in treating hidradenitis suppurativa in midstage study zbecker Mon, 03/11/2024 - 11:44
Legend CEO offers preview of high-stakes FDA adcomm for J&J-partnered Carvykti aliu Mon, 03/11/2024 - 11:11
Sun Pharma issues recall of gout drug due to microbial contamination jkeenan Mon, 03/11/2024 - 10:36
Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi fkansteiner Mon, 03/11/2024 - 10:30
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan kdunleavy Mon, 03/11/2024 - 10:27